Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
Holding BGNE?
Track your performance easily
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $215.00
Previous Close$197.51
Volume49.23K
Average Volume (3M)278.23K
Market Cap
$21.87B
Enterprise Value$26.84B
Total Cash (Recent Filing)$2.59B
Total Debt (Recent Filing)$7.59B
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 07, 2024EPS Estimate
-$1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.08
Shares Outstanding106,117,636
10 Day Avg. Volume276,600
30 Day Avg. Volume278,227
Standard Deviation0.14
R-Squared0.05
Alpha0.00719
Financial Highlights & Ratios
Price to Book (P/B)6.23
Price to Sales (P/S)6.73
Price to Cash Flow (P/CF)-55.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.67
Enterprise Value/Gross Profit12.91
Enterprise Value/Ebitda-52.10
Forecast
1Y Price Target
$266.44Price Target Upside34.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
BeiGene News
Bulls Say, Bears Say
Bulls Say
Manufacturing ExpansionThe plant's current 8kL capacity supports manufacturing of ~2M doses/year, but the next phase of construction should expand this to 16kL capacity and add capabilities for small molecule and ADC manufacturing in addition to biologics.
Market ShareBrukinsa is quickly emerging as the preferred BTKi in the US CLL market since approval only 6 quarters ago, capturing ~70% of the growth in the covalent BTKi class.
Product SalesZanubrutinib accounted for 53.2% of the overall domestic market in terms of sales.
Bears Say
Dividend PolicyDividend per share remains at zero.
Revenue ForecastThe revenue forecast for the coming years has been slightly lowered due to increasing competition in the BTK inhibitor market in China.
Sales PerformanceSelf-developed drug pamiparib saw a year-over-year sales decrease of 65.2%.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $215.00 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Nov 07, 2024 which is in 50 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Aug 27, 2024. The company reported -$1.15 earnings per share for the quarter, beating the consensus estimate of -$2.189 by $1.039.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$1.66.
How many shares outstanding does BeiGene have?
BeiGene has 97,225,975 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.15 in its last earnings report, beating expectations of -$2.189. Following the earnings report the stock price went up 1.481%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.44 (34.75% Upside)
$266.44 (34.75% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 46.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.40%
12-Months-Change
Fundamentals
Return on Equity
-14.62%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$266.44
▲(34.75% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
---